Institutional investors purchased a net $490.9 thousand shares of RNN during the quarter ended September 2014. This may signal that the smart money is gaining interest in this company as the 3.96% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 531.5 Thousand shares of Rexahn Pharmaceuticals In...
GEODE CAPITAL MANAGEMENT LLC Bought 201.4 Thousand shares of Rexahn Pharmaceuticals In...